Evidence map›Paper›PMID 26823709›Full record

ArticleInternational journal of clinical and experimental pathology2015

Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas.

Yin Li, Ke-Ping Xu, Dong Jiang, Jun Zhao, Jin-Feng Ge, Shi-Ying Zheng

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yin LiDepartment of Thoracic Surgery, Tumor Hospital of Henan Zhengzhou 450008, Henan Province, China.
Ke-Ping XuDepartment of Thoracic Surgery, Huai'an First People's Hospital, Nanjing Madical University Huaian, 223300, Jiangsu Province, China.
Dong JiangDepartment of Cardio-Thoracic Surgery, First Affiliated Hospital of Soochow University Suzhou 215006, Jiangsu Province, China.
Jun ZhaoDepartment of Cardio-Thoracic Surgery, First Affiliated Hospital of Soochow University Suzhou 215006, Jiangsu Province, China.
Jin-Feng GeDepartment of Cardio-Thoracic Surgery, First Affiliated Hospital of Soochow University Suzhou 215006, Jiangsu Province, China.
Shi-Ying ZhengDepartment of Cardio-Thoracic Surgery, First Affiliated Hospital of Soochow University Suzhou 215006, Jiangsu Province, China.
Soochow University · CNHenan Cancer Hospital · CNHuaian First People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLack of surface Fas expression is a main route for apoptotic resistance which is considered an important mechanism of tumorigenesis and tumor progression. Fas and FasL expression in 110 non-small cell lung carcinomas (NSCLCs) were investigated to evaluate their roles in pulmonary carcinogenesis and to examine the clinicopathologic significance of Fas expression with its relationship with p53 and bcl-2 over- expression.

methodsImmunohistochemical analysis using tissue microarray demonstrated that a large proportion of NSCLC patients (60%) showed lack of membranous Fas expression. The Fas-negative cases revealed the significantly lower survival rate than Fas-positive ones. Also, the loss of Fas receptor expression was found more frequently in advanced stage and higher nodal status. FasL protein was increased in most NSCLCs (89%) compared to normal lungs.

resultsp53 and bcl-2 overexpression showed no association with Fas expression. Conclusively, reduced membranous Fas expression as a mechanism of apoptotic resistance is considered to play an important part of the pulmonary carcinogenesis, which may predict poor survival and have a negative prognostic influence.

conclusionIncreased FasL expression is thought to be a basis for the immune evasion in NSCLCs. The rare bcl-2 overexpression suggests that this anti-apoptotic protein is unlikely to play a role in the apoptotic resistance of NSCLCs.

Indexed as

ApoptosisBiomarkers, TumorCarcinoma, Non-Small-Cell LungFas Ligand Proteinfas ReceptorFemaleHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingProto-Oncogene Proteins c-bcl-2Time FactorsTissue Array AnalysisBCL2 protein, humanBiomarkers, TumorFASLG protein, humanFas Ligand ProteinFAS protein, humanfas ReceptorProto-Oncogene Proteins c-bcl-2TP53 protein, humanTumor Suppressor Protein p53AntigenscarcinogenesiscarcinomaCD95FasL proteinnon-small-cell lung

Identifiers

PMID26823709
PMCPMC4713495
OpenAlexW2415110747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.